Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C

Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C

Abstract Background Patients with chronic hepatitis C virus (HCV) experience reduced quality of life, HCV-associated symptoms, comorbid conditions, and treatment side effects. The Cognitive Behavioral Coping Skills group intervention for HCV (CBCS-HCV) was developed using the Stage Model of Behavior...

Full description

Bibliographic Details
Main Authors:	Donna M. Evon, Carol E. Golin, Rachel Ruffin, Shauna Ayres, Michael W. Fried
Format:	Article
Language:	English
Published:	BMC 2018-06-01
Series:	Pilot and Feasibility Studies
Subjects:	Liver disease Patient-reported outcome measures Antiviral therapy Direct-acting antiviral Psychological Quality of life
Online Access:	http://link.springer.com/article/10.1186/s40814-018-0285-5

Similar Items

Development and pilot-testing of a cognitive behavioral coping skills group intervention for patients with chronic hepatitis C
by: Donna M. Evon, Ph.D., et al.
Published: (2017-06-01)

Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis
by: S N Batskikh, et al.
Published: (2018-11-01)

Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go
by: Juan-Carlos Saiz
Published: (2019-08-01)

Antivirals against the Chikungunya Virus
by: Verena Battisti, et al.
Published: (2021-07-01)

Update on Hepatitis C
Published: (2017)

Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients
by: Soraya Abad, et al.
Published: (2017-03-01)

Outcomes of liver transplantation in the era of modern antiviral therapy for hepatitis C
by: K. Yu. Kokina, et al.
Published: (2021-04-01)

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
by: Kwang Il Seo, et al.
Published: (2017-03-01)

Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients
by: Curtis L. Cooper, et al.
Published: (2017-11-01)

Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience
by: Alexandre Araujo, et al.
Published: (2019-05-01)

Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
by: Bernstein D, et al.
Published: (2019-02-01)

HCV-Specific T Cell Responses During and After Chronic HCV Infection
by: Hendrik Luxenburger, et al.
Published: (2018-11-01)

Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy
by: Rosanna Villani, et al.
Published: (2018-12-01)

Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
by: Yuri Cho, et al.
Published: (2015-12-01)

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
by: Soon Young Ko, et al.
Published: (2018-12-01)

Molecular Study of Occult Hepatitis C Infection among Iranian Hemophilia Patients Treated with Direct-acting Antiviral Agents
by: Elnaz Agi, et al.
Published: (2020-01-01)

Impact of Sustained Viral Response in the Evolution of Minimal Hepatic Encephalopathy: a Prospective Pilot Study
by: Marta Hernández-Conde, et al.
Published: (2019-01-01)

Impact of sustained viral response in the evolution of minimal hepatic encephalopathy: A prospective pilot study
by: Marta Hernández-Conde, et al.
Published: (2019-05-01)

Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs
by: Emily L.C. Tan, et al.
Published: (2004-04-01)

Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C
by: Lyalina, L., et al.
Published: (2022)

Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients
by: Crina Fofiu, et al.
Published: (2019-01-01)

Comparison of clinical outcomes and impact of SVR in American and Chinese patients with chronic hepatitis C
by: Huiying Rao, et al.
Published: (2020-08-01)

Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes
by: Giovana Rossato, et al.
Published: (2020-01-01)

Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study
by: Bahtiyar Yilmaz, et al.
Published: (2021-09-01)

Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
by: Mohamed M Sakr, et al.
Published: (2019-01-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study
by: Curtis L. Cooper, et al.
Published: (2019-08-01)

Chronic Hepatitis C Treatment with New Antiviral Agents
by: Özlem KANDEMİR
Published: (2018-12-01)

Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland
by: Karoline Aebi-Popp, et al.
Published: (2016-01-01)

Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil
by: Vinicius Lins Ferreira, et al.

CONCORDANCE OF NON-INVASIVE TESTS FOR LIVER FIBROSIS IN HCV PATIENTS PROPOSED FOR TREATMENT WITH DIRECT ACTING ANTIVIRALS
by: Andreea Cazan, et al.
Published: (2018-09-01)

Role of different direct-acting antiviral drugs on hepatitis C virus-associated mixed cryoglobulinemia in Egyptian patients
by: Tarek A Elshazly, et al.
Published: (2019-01-01)

Status of liver stiffness following directly acting antiviral treatment in patients with chronic hepatitis C: A Nepalese study
by: Dilip Sharma, et al.
Published: (2017-10-01)

Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida
by: Jose Armando Gonzales Zamora
Published: (2018-06-01)

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study
by: Luca Rinaldi, et al.
Published: (2019-08-01)

Evolution of Pretreatment Assessment and Direct Acting Antiviral Regimens in Accordance with Upgrading Guidelines: A Retrospective Study in HIV/HCV Coinfected Patients
by: Zachary Henry, et al.
Published: (2018-09-01)

Potential Antiviral Options against SARS-CoV-2 Infection
by: Aleksandr Ianevski, et al.
Published: (2020-06-01)

A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety
by: Akira Sakamaki, et al.
Published: (2019-06-01)

Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response
by: Chun-Ming Hong, et al.
Published: (2017-04-01)

Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients
by: Hsu-Heng Yen, et al.
Published: (2021-03-01)

Cannot write session to /tmp/vufind_sessions/sess_8pftn68l06qrv06mml2u2fi3hb